Treatment and follow-up results of WHO grade II meningiomas

J Clin Neurosci. 2021 Sep:91:354-364. doi: 10.1016/j.jocn.2021.07.022. Epub 2021 Jul 30.

Abstract

Meningiomas are the most common primary intracranial tumors. They have three pathologic grades. Surgical resection aiming Simpson I resection is the standard treatment for meningiomas. Radiotherapy and Gamma Knife radiosurgery are the main adjuvant and salvage treatments. Chemotherapy has limited use. Grade II, and III meningiomas have a higher recurrence rate, and adjuvant radiotherapy is usually the standard treatment for grade III meningiomas but there is not a consensus regarding grade II meningiomas. In this paper, we analyzed our meningioma series of 1401 patients and presented the treatment and follow-up results of 170 grade II meningioma cases. The median follow-up of grade II meningiomas was 61 (range = 1-231) months. The mean age of patients was 52.5 ± 15.0 years, 102 of them were female and 68 were male (female/male ratio = 1.5). The median progression-free survival (PFS) of them was 109 months, and the cumulative overall survival (OS) rate was 85% at 10 years. Meningiomas with gross total resection, non-skull base meningiomas, and primary grade II meningiomas had longer PFS with statistical significance, while non-skull base meningiomas, younger group of patients, and primary grade II meningiomas had longer OS with a statistical significance.

Keywords: Atypical meningiomas; Chordoid meningiomas; Clear cell meningiomas; Grade II meningiomas; Meningiomas.

MeSH terms

  • Child
  • Female
  • Follow-Up Studies
  • Humans
  • Infant, Newborn
  • Male
  • Meningeal Neoplasms* / therapy
  • Meningioma* / surgery
  • Neoplasm Recurrence, Local / epidemiology
  • Retrospective Studies
  • Treatment Outcome
  • World Health Organization